Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Red de Investigación Rápida en Desarrollo de Diagnósticos para TB (R2D2TB Network)

4 de noviembre de 2026 actualizado por: University of California, San Francisco

Investigación rápida en el desarrollo de diagnósticos para el estudio de la red de TB (R2D2 TB Network)

To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study seeks to identify and rigorously assess promising early stage tuberculosis (TB) triage, diagnostic and drug resistance tests (hereafter referred to as "novel tests") in clinical studies conducted in settings of intended use. Rapid diagnosis, identification of drug resistance and effective treatment are critical for improving patient outcomes and reducing TB transmission. However, analysis of care cascades and prevalence surveys indicate that 40-60% of patients with TB are not initiated on effective treatment.1,2 The different types of tests required to reduce this "diagnostic gap" have been described in the form of target product profiles (TPPs). The highest- priority TPPs are for: 1) a point-of-care, non-sputum biomarker-based test to facilitate rapid TB diagnosis using easily accessible samples (a biomarker-based diagnostic test) and 2) a simple, low-cost test that can be used by front-line health workers to rule-out TB (a triage test). The R2D2 TB Network study will evaluate the sensitivity and specificity of novel triage and diagnostic tests against a reference standard including sputum Xpert® MTB/RIF (Mycobacterium tuberculosis/Rifampin) Ultra and sputum mycobacterial culture. The sensitivity and specificity of rapid drug susceptibility tests (rDST) will be compared against a reference standard including culture-based phenotypic DST and whole genome sequencing (WGS) of mycobacterial DNA. In addition, the usability of novel tests will be assessed through direct observations and surveys of routine health workers.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

26436

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Dasmariñas, Filipinas
        • Reclutamiento
        • De La Salle Medical and Health Sciences Institute
        • Contacto:
      • Vellore, India
        • Reclutamiento
        • Chitoor (Christian Medical College satellite campus)
        • Contacto:
      • Vellore, India
        • Reclutamiento
        • Christian Medical College CMC Pulmonary Outpatient Department
        • Contacto:
      • Vellore, India
        • Reclutamiento
        • Primary care clinics (Shalom/LCC, CHAD)
        • Contacto:
      • Cape Town, Sudáfrica
        • Reclutamiento
        • Brooklyn Chest Hospital
        • Contacto:
      • Cape Town, Sudáfrica
        • Reclutamiento
        • Khayelitsha District Health Center
        • Contacto:
      • Cape Town, Sudáfrica
        • Reclutamiento
        • Scottsdene primary care clinic
        • Contacto:
      • Cape Town, Sudáfrica
        • Reclutamiento
        • Wallacedene primary care clinic
        • Contacto:
      • Cape Town, Sudáfrica
        • Reclutamiento
        • Kraaifontein Community Health Clinic
        • Contacto:
      • Kampala, Uganda
        • Reclutamiento
        • Kisenyi Health Center
        • Contacto:
      • Kampala, Uganda
        • Reclutamiento
        • Mulago Outpatient Department
        • Contacto:
      • Hanoi, Vietnam
        • Reclutamiento
        • Hanoi Lung Hospital, Outpatient departments
        • Contacto:
      • Hanoi, Vietnam
        • Reclutamiento
        • National Lung Hospital, Outpatient departments
        • Contacto:
      • Lusaka, Zambia
        • Reclutamiento
        • Centre for Infectious Disease Research in Zambia
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Novel TB triage and diagnostic tests:

We will include non-hospitalized adults (age ≥ 12 years) with either 1) cough ≥2 weeks' duration, a commonly accepted criterion for identifying people with presumed pulmonary TB (to facilitate standardization across sites and comparison of test performance across sub-groups or 2) risk factors for which TB screening is recommended (HIV infection, self-reported close contact, history of mining work). People with risk factors will be included if they screen positive for TB based on WHO-recommended screening tools as specified below:

Positive TB screening definitions by risk factor:

  1. PLHIV (Risk Factor), CRP >5 mg/dL OR abnormal CXR (Positive TB screening definition)
  2. Self-reported Close Contact (Risk Factor), abnormal CXR (Positive TB screening definition)
  3. History of mining work (Risk Factor), abnormal CXR (Positive TB screening definition)

We will exclude people who:

  1. completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
  2. have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives);
  3. reside >20km from the study site or are unwilling to return for follow-up visits; or
  4. are unwilling to provide informed consent

Novel TB rDST assays:

We will include adults (age ≥12 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus). We will exclude people who:

  1. have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures
  2. are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment
  3. are unable or unwilling to provide informed consent

Assessment of the usability of novel TB tests:

We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). We will exclude staff who are unwilling to provide informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Evaluation of various novel TB triage and diagnostic tests.

For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.

We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.

We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.

We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.

We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.

We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).

We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.

Experimental: Evaluation of novel rDST assays

Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate targeted and whole genome sequencing assays.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity
Periodo de tiempo: 7 months

Number of positive results for a given index test/(Total positive + negative results for a given index test) among patients with TB using the microbiological reference standard

7 months
Specificity
Periodo de tiempo: 7 months

Number of negative results for a given index test/(Total positive + negative results for a given index test) among patients without TB using the microbiological reference standard

7 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Adithya Cattamanchi, MD, University of California, San Francisco

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de abril de 2021

Finalización primaria (Estimado)

31 de mayo de 2031

Finalización del estudio (Estimado)

31 de mayo de 2031

Fechas de registro del estudio

Enviado por primera vez

7 de junio de 2021

Primero enviado que cumplió con los criterios de control de calidad

7 de junio de 2021

Publicado por primera vez (Actual)

11 de junio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • U01AI152087 (Subvención/contrato del NIH de EE. UU.)
  • R01AI190419 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .